Related Experiment Video
Updated: May 23, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
SREBP1 Transactivation of NHE3 Impairs Cardiac Contraction and Aggravates Heart Failure
Huijun Gu1,2, Jianpei Wen3, Yiyi Liu1
1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Institute of Advanced Clinical Medicine, Peking University; National Health Commission (NHC) Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides; Beijing Key Laboratory of Cardiovascular Receptors Research; Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing 100191, China (H.G., Y.L., Y.X., M.Z., L.B., H.C., W.Z., W.X., K.W., Y.D., X.Y., H.W., J.H., E.D., Y. Zhang, H.X.).
Insights
Sterol regulatory element-binding protein 1 (SREBP1) directly activates sodium-hydrogen exchanger 3 (NHE3) in heart failure with reduced ejection fraction (HFrEF). This leads to calcium handling dysregulation and impaired cardiac contractility, identifying a new therapeutic target for HFrEF.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Heart Failure Pathophysiology
Background:
- Heart failure with reduced ejection fraction (HFrEF) involves impaired cardiac contractility and high mortality, linked to intracellular ion cycling dysregulation.
- Mechanisms connecting myocardial stress to ion dysregulation in HFrEF are not fully understood.
- The role of metabolic transcription factor SREBP1 in HFrEF, particularly ion handling without metabolic comorbidities, remains undefined.
Purpose of the Study:
- To investigate the role of sterol regulatory element-binding protein 1 (SREBP1) in the pathophysiology of heart failure with reduced ejection fraction (HFrEF).
- To determine if SREBP1 directly influences ion handling, specifically the sodium-hydrogen exchanger 3 (NHE3), in the failing heart.
- To explore the therapeutic potential of targeting the SREBP1-NHE3 pathway in HFrEF.
Main Methods:
- Analysis of cardiac tissues from HFrEF patients and mice with transverse aortic constriction (TAC)-induced HFrEF.
- Generation of cardiomyocyte-specific SREBP1 transgenic (Srebp1a-Tg) and knockdown (Cre-Srebp1f/f) mouse models.
- Utilized AAV9 vectors for manipulating NHE3 and SREBP1 expression in cardiomyocytes to validate findings.
Main Results:
- SREBP1 was activated in human and mouse HFrEF hearts, directly transactivating the sodium-hydrogen exchanger 3 (NHE3) gene.
- SREBP1 activation led to impaired cardiac contractility and dysregulated calcium handling, associated with increased NHE3 activity.
- Knockdown of SREBP1 or NHE3 in cardiomyocytes restored calcium handling and improved cardiac function in HFrEF models.
Conclusions:
- SREBP1 directly upregulates cardiac NHE3 during HFrEF progression, causing ion dysregulation and contractile dysfunction.
- This study reveals a novel, noncanonical role for SREBP1 in heart failure pathophysiology.
- The SREBP1-NHE3 axis represents a potential new therapeutic target for HFrEF.
Background:
Heart failure with reduced ejection fraction (HFrEF) is characterized by impaired contractility and high mortality. Dysregulation of intracellular ion (ie, Na+/H+ and Ca2+) cycling underlies reduced cardiac contractility. The mechanisms linking myocardial stress to this ion dysregulation remain incompletely understood. Although the metabolic transcription factor SREBP1 (sterol regulatory element-binding protein 1) remodels cardiac metabolism, its role in HFrEF without metabolic comorbidities, particularly regarding ion handling, remains undefined.
Methods:
Cardiac tissues from HFrEF patients and mice subjected to transverse aortic constriction (TAC) were analyzed for SREBP1 transactivation of sodium-hydrogen exchanger 3 (NHE3). Cardiomyocyte-specific SREBP1 transgenic (Srebp1a-Tg) and knockdown (Cre-Srebf1f/f) mice were generated. AAV9 vectors carrying Slc9a3 (encoding NHE3), Srebp1a or shRNA against Slc9a3, driven by the cardiomyocyte-specific cTnT promoter, were used to validate the role of the SREBP1-NHE3 in HFrEF.
Results:
SREBP1 was activated in human hearts with HFrEF because of dilated cardiomyopathy, but without diabetes or hyperlipidemia, and in TAC-induced HFrEF mouse hearts. Srebp1a-Tg mice exhibited impaired cardiac contractility with dysregulated calcium handling in cardiomyocytes without apparent lipid accumulation. Transcriptomics analysis identified increased NHE3 expression in Srebp1a-Tg mice, confirmed by NHE3 upregulation in TAC hearts and human failing hearts. ChIP-seq, ChIP, and promoter reporter assay demonstrated direct transcriptional regulation of SLC9A3 (encoding NHE3) by SREBP1. NHE3 activity was enhanced in cardiomyocytes isolated from Srebp1a-Tg mice or those underwent TAC, whereas cardiomyocyte-specific Srebf1 knockdown in TAC mice reduced NHE3 activity. Cardiomyocyte-specific knockdown of Srebf1 or Slc9a3 restored calcium handling and improved cardiac function in TAC mice. In Srebp1a-Tg mice, NHE3 knockdown alleviated Na+ and Ca2+ overload and rescued cardiac systolic dysfunction. Conversely, NHE3 overexpression caused contractile impairment in both Cre-Srebf1f/f mice and controls, which offset the protective effect because of SREBP1 loss in the context of Na+ and Ca2+ overload.
Conclusions:
SREBP1 directly transactivates cardiac NHE3 during the progression of HFrEF, leading to dysregulated calcium handling and impaired contractility, revealing a novel, noncanonical role for SREBP1 in the pathophysiology of heart failure and offering a potential new therapeutic target.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inotropic Agents
Regulation of the Unfolded Protein Response